As discovered by pathological mechanisms in recent clinical research, as a serum reactant, ACPA has a direct connection with bone erosion in RA patients, with the manifestations of increased possibility of severe cartilage and bone damage, and a worse prognosis accompanied by severe joint deformities (62, 63). Here, PRTN3 is linked to rheumatoid arthritis.